Jakafi and Hypersensitivity - a phase IV clinical study of FDA data

Summary:

Hypersensitivity is reported as a side effect among people who take Jakafi (ruxolitinib phosphate), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Vitamin D3, and have Polycythaemia vera.

The phase IV clinical study analyzes which people have Hypersensitivity when taking Jakafi. It is created by eHealthMe based on reports of 56,447 people who have side effects when taking Jakafi from the FDA, and is updated regularly.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

What is Hypersensitivity?

Hypersensitivity is found to be associated with 2,755 drugs and 2,913 conditions by eHealthMe. Check the latest studies of Hypersensitivity.

On Jul, 05, 2026

56,447 people reported to have side effects when taking Jakafi.
Among them, 307 people (0.54%) have Hypersensitivity.

Among these 307 people:

* Approximation only. Some reports may have incomplete information.

Do you take Jakafi and have Hypersensitivity?

- Check whether Hypersensitivity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Jakafi:

Jakafi (56,530 reports)

Hypersensitivity treatments and more:

Hypersensitivity (272,618 reports)

How severe was Hypersensitivity and when was it recovered:

Hypersensitivity in Jakafi

Expand to all the drugs that have ingredients of ruxolitinib phosphate:

Hypersensitivity and drugs with ingredients of ruxolitinib phosphate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Jakafi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypersensitivity:

Hypersensitivity (2,755 drugs)

Browse all the conditions that are associated with Hypersensitivity:

Hypersensitivity (2,913 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ruxolitinib phosphate (the active ingredients of Jakafi) and Jakafi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.